Adaptive Phage Therapeutics, a pharmaceutical company, agreed to merge with BiomX, a clinical-stage company. Financial terms were not disclosed. “Today’s announcement sends a clear vote of confidence from leading biotechnology investors who led this transaction that phage technology holds significant potential to treat serious infections with significant unmet need and limited treatment options. In the case of CF, BX004 has the potential to improve lung function in patients with chronic and potentially deadly pulmonary infections,” Jonathan Solomon, BiomX CEO.